Drug Shortage Report for JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE
| Report ID | 137069 |
| Drug Identification Number | 02418223 |
| Brand name | JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE |
| Common or Proper name | Irbesartan HCTZ Tablets |
| Company Name | JAMP PHARMA CORPORATION |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | IRBESARTAN HYDROCHLOROTHIAZIDE |
| Strength(s) | 150MG 12.5MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 100 |
| ATC code | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2019-10-07 |
| Estimated end date | 2022-12-30 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2021-04-07 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1310 RUE NOBEL BOUCHERVILLE, QUEBEC CANADA J4B 5H3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2021-04-07 | English | Compare |
| v2 | 2021-04-07 | French | Compare |
Showing 1 to 2 of 2